# Vivos Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Vivos Inc). ## Overview Vivos Inc. is a U.S.-based radiation oncology medical device company focused on yttrium-90 (Y-90) precision radionuclide therapy technologies for treating non-resectable tumors. Its core platform includes RadioGel™ and related brachytherapy and isotope-based products developed for use in human and animal cancer treatment. ## Products & services • RadioGel™ precision radionuclide therapy device • Y-90 based brachytherapy products • IsoPet® animal therapy procedures • Precision radionuclide therapy development • Regulatory and commercialization support for isotope therapies - **Precision radionuclide therapy devices** (55%) — Y-90 based devices and therapies designed to deliver radiation to non-resectable tumors. - **Animal therapy procedures** (35%) — IsoPet® treatments administered through veterinary and clinic settings. - **Research and development services** (10%) — Development work on new isotope technologies and future cancer applications. - RadioGel™ precision radionuclide therapy device - Y-90 based brachytherapy products - IsoPet® animal therapy procedures - Precision radionuclide therapy development - Regulatory and commercialization support for isotope therapies ## Customers The company sells into oncology and veterinary treatment settings that use isotope-based therapies for tumors and other cancers. Its customer base includes clinics, physicians, and treatment partners that adopt the technology for either human oncology or animal therapy applications. Commercialization also depends on third-party manufacturing, distribution, licensing, and partnership arrangements. - **Veterinary clinics and animal therapy centers** (primary) — Buy or administer IsoPet® procedures for animal tumor treatment and related oncology care. - **Human oncology clinics and hospitals** (primary) — Potential future buyers of RadioGel™ and other precision radionuclide therapies for non-resectable tumors. - **Clinical research and regulatory partners** (secondary) — Support studies, approvals, and evidence generation needed for broader commercialization. - **Manufacturing and commercialization partners** (secondary) — Provide outsourced production, sales, distribution, and licensing capabilities. - Veterinary clinics using IsoPet® for animal tumor treatment - Oncology physicians and treatment centers for future human use - Clinical partners supporting regulatory and trial activity - Manufacturing and distribution partners for commercialization - Licensing partners outside the United States ## Geography Vivos is headquartered in Washington State in the United States, and its current commercial activity has been concentrated in the Northwestern U.S. The company also describes a broader U.S. animal therapy marketing effort and a longer-term plan to pursue international approvals and licensing outside the United States. - Headquartered in Kennewick, Washington - Current focus has been the Northwestern United States - Animal therapy marketing has expanded to other U.S. regions - Future commercialization is intended to extend outside the U.S. - International growth depends on approvals and licensing partners ## Strategy Vivos’ strategy centers on advancing regulatory approval for its Y-90 precision radionuclide therapy platform and expanding the clinical use of IsoPet® and related products. It also plans to rely on licensing, partnerships, and outsourced manufacturing and distribution to commercialize the technology in the U.S. and abroad. - **Secure regulatory clarity and approvals** (short-term) — FDA classification and approval timing determine the path to human commercialization. - **Build recurring clinical usage** (medium-term) — Broader clinic adoption is needed to scale IsoPet® and future therapy revenue. - **Establish commercialization partners** (medium-term) — Third-party manufacturing and licensing reduce the need for a large internal sales force. - Advance FDA classification and approval path for RadioGel™ - Expand IsoPet® treatment adoption across regional clinics - Use licensing and partnership agreements to fund growth - Outsource manufacturing, sales, and distribution after approval - Pursue regulatory approvals and commercialization outside the U.S. ## Risks The business depends on regulatory outcomes, clinical evidence, and the ability to fund development until commercialization scales. It also faces financing risk, execution risk in outsourced manufacturing and distribution, and the normal adoption risk of a specialized medical device platform in a regulated healthcare market. - **Regulatory approval risk** [high] — Commercialization depends on FDA classification and possible additional studies. - **Financing and going-concern risk** [critical] — The company has limited revenue and relies on external capital to fund operations. - **Commercialization execution risk** [high] — Success depends on third-party manufacturing, sales, distribution, and licensing. - **Clinical adoption risk** [medium] — Hospitals and clinics may adopt the therapy slowly without strong evidence and approvals. - FDA classification and approval timing could delay commercialization - Additional clinical studies may be required before broader use - Financing needs may exceed available capital - Outsourced manufacturing and distribution add execution risk - Adoption of new cancer therapies can be slow and uncertain ## Accounting Revenue recognition is important because the company’s reported sales are still small and appear tied to specific procedures and product-related activity. Investors should also watch estimates around inventory, research and development spending, stock-based compensation, and going-concern disclosures, since these can materially affect reported losses and balance sheet presentation. - **Revenue recognition** — Can create quarter-to-quarter volatility in reported sales - **Inventory and cost of goods sold** — Can shift gross margin and cost timing across periods - **Stock-based compensation** — Raises reported operating costs without cash outflow - **Going-concern assessment** — Affects disclosure and investor assessment of solvency risk - Revenue recognition depends on procedure timing and product delivery - Inventory build can shift cost of goods sold between periods - Stock-based compensation is included in professional fees - R&D spending reflects development and regulatory work - Going-concern disclosure signals heavy reliance on estimates and funding --- *Last updated: 2026-04-29T05:07:09.708361+00:00*